52222-73-8

Usage

Uses

Used in Pharmaceutical Industry:
4-(trifluoromethyl)-1H-pyrazole is used as a pharmaceutical intermediate for the synthesis of various medicinal compounds. Its unique structure and reactivity make it a valuable building block in the development of new drugs with improved pharmacological properties.
Used in Chemical Synthesis:
In the field of chemical synthesis, 4-(trifluoromethyl)-1H-pyrazole is utilized as a key intermediate in the preparation of a wide range of chemical compounds. Its palladium-catalyzed cross-coupling reactions with aryl iodides have been shown to provide high yields of the corresponding 5-aryl-4-fluoro-1H-pyrazoles, which are important for the development of new chemical entities with potential applications in various industries.

Upstream product

• 460-40-2 3,3,3-trifluoropropanal 
• 3724-43-4 Vilsmeier reagent 
• 176214-18-9 N-[3-(dimethylamino)-2-(trifluoromethyl)-2-propenylidene]-N-dimethylammonium chloride 

Downstream Products

• 1393125-34-2 4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)benzonitrile 
• 1393126-10-7 5-bromo-3-methyl-2-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyridine 
• 1459258-32-2 N-isopropyl-1-(4-methoxybenzyl)-3-(4-(trifluoromethyl)-1H-pyrazol-1-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine 
• 1393125-27-3 4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]benzaldehyde 
• 1393125-56-8 1-(4-nitrophenyl)-4-(trifluoromethyl)-1H-pyrazole 
• 1393126-61-8 methyl 4-(4-methyl-1-(4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)pent-1-en-2-yl)benzoate 
• 1393126-58-3 (+/-)-5-bromo-2-(1-(4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)phenoxy)butyl)pyridine 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

BIARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are compounds for treatment of KIT, CSF-1R and/or FLT3 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Process for preparing haloalkyl(thio)vinimidinium salts and 4-(haloalkyl(thio))pyrazoles and their conversion to crop protection compositions

A process for preparing compounds of the formula (IX) by a) reaction of haloalkyl(thio)acetic acids of the formula (II) with formamides of the formula (III) to give vinimidinium salts of the formula (I), b) reaction of vinimidinium salts of the formula (I) with hydrazines of the formula (V) to give pyrazoles of the formula (IV) c) base-catalyzed reaction of compounds of the formula (VI) with pyrazoles of the formula (IV) to give compounds of the formula (VII) and d) base-catalyzed reaction of compounds of the formula (VII) with compounds of the formula (VIII), in which R1 to R5 are various radicals such as alkyl, X are substituted aromatic radicals such as phenyl, and Z is CH or N.

Positive allosteric modulators of the nicotinic acetylcholine receptor

The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which α7 nAChR is known to be involved.

Preparation of novel β-trifluoromethyl vinamidinium salt and its synthetic application to trifluoromethylated heterocycles

β-Trifluoromethylated vinamidinium salt (1) was prepared in high yield by the reaction between 3,3,3-trifluoropropanoic acid and phosphorus oxychloride in N,N,-dimethylformamide at 70°C for 1h. This salt 1 reacted readily with bifunctional nitrogen nucleophiles, such as amidine and hydrazine derivatives, in acetonitrile or dimethyl sulfoxide to furnish the corresponding trifluoromethylated azaheterocycles in good yields.